Health Care & Life Sciences » Pharmaceuticals | Jiangsu Hengrui Medicine Co. Ltd.

Jiangsu Hengrui Medicine Co. Ltd. A | Balance Sheet

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
2,169
3,449
5,133
6,442
8,817
10,953
Total Accounts Receivable
2,609
2,987
3,472
3,859
4,531
5,517
Inventories
430
551
523
637
790
1,031
Other Current Assets
204
213
251
455
330
569
Total Current Assets
5,412
7,200
9,378
11,393
14,469
18,069
Net Property, Plant & Equipment
1,564
1,624
1,770
2,474
3,079
3,686
Total Investments and Advances
5
5
79
81
118
156
Intangible Assets
203
200
196
285
279
273
Other Assets
-
-
-
5
6
65
Total Assets
7,220
9,087
11,497
14,330
18,039
22,361
ST Debt & Current Portion LT Debt
18
23
112
43
528
Accounts Payable
282
396
492
755
734
Income Tax Payable
13
75
144
118
151
Other Current Liabilities
241
220
305
448
637
Total Current Liabilities
554
715
1,053
1,365
2,050
Long-Term Debt
10
10
-
-
-
Deferred Taxes
37
58
73
93
90
Total Liabilities
564
725
1,053
1,365
2,050
Common Equity (Total)
6,357
7,934
9,931
12,388
15,368
Total Shareholders' Equity
6,357
7,934
9,931
12,388
15,368
Total Equity
6,656
8,290
10,358
12,874
15,943
Liabilities & Shareholders' Equity
7,220
9,087
11,497
14,330
18,039
Accumulated Minority Interest
299
355
426
486
575
Non-Equity Reserves
-
72
86
91
46

About Jiangsu Hengrui Medicine Co.

View Profile
Address
No. 7 Kunlunshan Road
Lianyungang Jiangsu 222000
China
Employees -
Website http://www.hrs.com.cn
Updated 07/08/2019
Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. Its products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; film and gel.